SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
OSI Pharmaceuticals (OSIP) - formerly Oncogene
An SI Board Since December 1997
Posts SubjectMarks Bans Symbol
447 40 0 OSIP
Emcee:  James Reynolds Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
372Does anyone know the current runrate for Macugen. Also future projection for FDAdavid nordic-3/3/2006
371[Macugen 2 year systemic safety data is clean] from Briefing.com: >>8:10tuck-2/24/2006
370Tuck- This came out today: Merck Announces FDA Acceptance of New Drug ApplicatBiotech Jim-2/15/2006
369>>MELVILLE, N.Y.--(BUSINESS WIRE)--Feb. 15, 2006--OSI Pharmaceuticals, Inctuck-2/15/2006
368I reread ACL’s PR from 12/12/05 and it states that the drug to be tested with ReDewDiligence_on_SI-2/10/2006
367The NEI is testing Alcon’s Retaane in combination with “a monoclonal antibody” fDewDiligence_on_SI-2/9/2006
366Colin Goddard: There's an outstanding question, one that absolutely fascinascaram(o)uche-2/8/2006
365My further 2 cents I think deep down, Goddard is rather insecure about his capaformer_pgs-2/8/2006
364What I don't get about Goddard's way of thinking is yes, osip will be varkrw-2/8/2006
363I agree with your thoughts. What's even more scary about the cell pathways former_pgs-2/8/2006
362Speaking of stupid acquisitions, there's also Cell Pathways. Given that thetuck-2/8/2006
361Tuck, If memory serve me well, Biotech Jim is skeptical about DP-IV inhibitors.Miljenko Zuanic-2/7/2006
360Thanks to masterlongevity of Ihub for digging up this estimate by Wachovia of thtuck-2/7/2006
359Old (2002), but interesting review of the patent literature for DP-IV inhibitorstuck-2/7/2006
358<<It'll be interesting to see if Tarceva gets into 2nd line in Europe Miljenko Zuanic-2/7/2006
357Ricarduno of the YMB board provides notes on the ML conference: finance.messagetuck-2/7/2006
356My goodness Tuck and Miljenko..I came over here to find Miljenko to show him an zeta1961-2/7/2006
355Finally, common sense voice! Ophthalmology Volume 113, Number 3, March 2006 …1Miljenko Zuanic-2/7/2006
354Avastin results in AMD (thanks to Masterlongevity of IHub, but not clear to me wtuck-2/6/2006
353<i>A little late…</i> investorshub.com Are you a hockey fan?DewDiligence_on_SI-2/6/2006
352>>11:32AM OSI Pharm announces two corporate governance changes (OSIP) 28.1tuck-2/6/2006
351Thanks—that’s probably the answer.DewDiligence_on_SI-2/1/2006
350I figure the other $9 million came in September, which is in the 2nd Q. They hatuck-2/1/2006
349275+25=309?DewDiligence_on_SI-2/1/2006
348Tarceva world-wide sales for 2005 = $309 million >>MELVILLE, N.Y.--(BUSINtuck-2/1/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News